These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Peloquin J; Wei X; White K; Cheng A; Martin H; Quirk E Lancet HIV; 2017 Apr; 4(4):e154-e160. PubMed ID: 28219610 [TBL] [Abstract][Full Text] [Related]
43. Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection. Scott LJ Drugs; 2020 Jan; 80(1):61-72. PubMed ID: 31865558 [TBL] [Abstract][Full Text] [Related]
44. Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey. Musengimana G; Tuyishime E; Kiromera A; Malamba SS; Mulindabigwi A; Habimana MR; Baribwira C; Ribakare M; Habimana SD; DeVos J; Mwesigwa RCN; Kayirangwa E; Semuhore JM; Rwibasira GN; Suthar AB; Remera E Antivir Ther; 2022 Jun; 27(3):13596535221102690. PubMed ID: 35593031 [TBL] [Abstract][Full Text] [Related]
45. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. Patel DA; Snedecor SJ; Tang WY; Sudharshan L; Lim JW; Cuffe R; Pulgar S; Gilchrist KA; Camejo RR; Stephens J; Nichols G PLoS One; 2014; 9(9):e105653. PubMed ID: 25188312 [TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. Rojas J; de Lazzari E; Negredo E; Domingo P; Tiraboschi J; Ribera E; Abdulghani N; Puig J; Mateo MG; Podzamczer D; Gutierrez MM; Paredes R; Clotet B; Gatell JM; Blanco JL; Martínez E; Lancet HIV; 2021 Aug; 8(8):e463-e473. PubMed ID: 34358497 [TBL] [Abstract][Full Text] [Related]
47. Longitudinal viral load outcomes of adults with HIV after detectable viremia on tenofovir, lamivudine, and dolutegravir. Sodeke O; Milligan K; Ezeuko I; Oladipo A; Emeh A; Bashorun A; Orisawayi O; Danjuma S; Onotu D; Boyd AM; Abutu A; Chun H; Vallabhaneni S AIDS; 2024 Sep; 38(11):1714-1719. PubMed ID: 38870005 [TBL] [Abstract][Full Text] [Related]
48. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial. Osiyemi O; De Wit S; Ajana F; Bisshop F; Portilla J; Routy JP; Wyen C; Ait-Khaled M; Leone P; Pappa KA; Wang R; Wright J; George N; Wynne B; Aboud M; van Wyk J; Smith KY Clin Infect Dis; 2022 Sep; 75(6):975-986. PubMed ID: 35079789 [TBL] [Abstract][Full Text] [Related]
49. Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV-Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial. Wang R; Sun L; Wang X; Zhai Y; Wang L; Ma P; Wu C; Zhou Y; Chen R; Wang R; Zhang F; Hua W; Li A; Xia W; Gao Y; Li R; Lv S; Shao Y; Cao Y; Zhang T; Wu H; Cai C; Dai L Clin Infect Dis; 2024 Jul; 79(1):169-176. PubMed ID: 38236137 [TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial. Sculier D; Wandeler G; Yerly S; Marinosci A; Stoeckle M; Bernasconi E; Braun DL; Vernazza P; Cavassini M; Buzzi M; Metzner KJ; Decosterd LA; Günthard HF; Schmid P; Limacher A; Egger M; Calmy A; PLoS Med; 2020 Nov; 17(11):e1003421. PubMed ID: 33170863 [TBL] [Abstract][Full Text] [Related]
51. Brief Report: Virologic Impact of the Dolutegravir Transition: Prospective Results From the Multinational African Cohort Study. Allahna E; Nicole D; Neha S; Hannah K; Jonah M; John O; Valentine S; Emmanuel B; Michael I; Trevor A C; Christina S P; Joseph S C; Julie A A; J Acquir Immune Defic Syndr; 2022 Nov; 91(3):285-289. PubMed ID: 35980350 [TBL] [Abstract][Full Text] [Related]
52. Dolutegravir Plus Lamivudine as Initial Therapy for HIV-1 Infected and ARV-naïve Patients in West China, 24-Weeks Results of a Preliminary Real-world Study. Hui X; Gan X; Li Q; Sun W Curr HIV Res; 2022; 20(3):222-227. PubMed ID: 35570525 [TBL] [Abstract][Full Text] [Related]
53. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353. Nyaku AN; Zheng L; Gulick RM; Olefsky M; Berzins B; Wallis CL; Godfrey C; Sax PE; Acosta EP; Haas DW; Smith KY; Sha BE; Van Dam CN; Taiwo BO; J Antimicrob Chemother; 2019 May; 74(5):1376-1380. PubMed ID: 30668695 [TBL] [Abstract][Full Text] [Related]
54. Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment. Steegen K; Levin L; Evans D; Technau KG; Hans L Pediatr Infect Dis J; 2022 Oct; 41(10):827-834. PubMed ID: 35895893 [TBL] [Abstract][Full Text] [Related]
55. Effectiveness, Weight Changes, and Metabolic Outcomes on Switch to Generic Dolutegravir/Lamivudine Among People with HIV in Western India: An Observational Study. Pujari S; Gaikwad S; Panchawagh S; Chitalikar A; Joshi K; Rohekar C; Dabhade D; Bele V AIDS Res Hum Retroviruses; 2024 Apr; 40(4):204-215. PubMed ID: 38063004 [TBL] [Abstract][Full Text] [Related]
56. Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART. Derache A; Iwuji CC; Danaviah S; Giandhari J; Marcelin AG; Calvez V; de Oliveira T; Dabis F; Pillay D; Gupta RK J Antimicrob Chemother; 2019 Feb; 74(2):473-479. PubMed ID: 30380053 [TBL] [Abstract][Full Text] [Related]
57. Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial. Griesel R; Zhao Y; Simmons B; Omar Z; Wiesner L; Keene CM; Hill AM; Meintjes G; Maartens G Lancet HIV; 2023 Jul; 10(7):e433-e441. PubMed ID: 37230101 [TBL] [Abstract][Full Text] [Related]
58. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227 [TBL] [Abstract][Full Text] [Related]
59. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. Sax PE; Tierney C; Collier AC; Fischl MA; Mollan K; Peeples L; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Koletar SL; Johnson VA; Geiseler PJ; Daar ES; N Engl J Med; 2009 Dec; 361(23):2230-40. PubMed ID: 19952143 [TBL] [Abstract][Full Text] [Related]
60. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. Borghetti A; Lombardi F; Gagliardini R; Baldin G; Ciccullo A; Moschese D; Emiliozzi A; Belmonti S; Lamonica S; Montagnani F; Visconti E; De Luca A; Di Giambenedetto S BMC Infect Dis; 2019 Jan; 19(1):59. PubMed ID: 30654739 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]